第1相試験:進行性消化器がん患者におけるDISP-10の評価
進行消化器がん患者を対象にDISP-10の安全性と有効性を評価する第1相試験
This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor [CAR] T), in adult participants with advanced gastrointestinal (GI) cancers.
The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Dispatch Clinical
- 電話番号:(215) 792-4699
- メール:clinicaltrials@dispatchbio.com
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- 募集
- City of Hope
-
Newport Beach、California、アメリカ、92663
- 募集
- Hoag Memorial Hospital Presbyterian
-
-
Florida
-
Tampa、Florida、アメリカ、33612
- 募集
- Moffitt Cancer Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Dana-Farber Cancer Institute
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45267
- 募集
- University of Cincinnati Cancer Center
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- まだ募集していません
- Tennessee Oncology
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- 募集
- Huntsman Cancer Institute
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Histologically confirmed advanced or metastatic esophageal, gastroesophageal junction, gastric adenocarcinoma, colorectal adenocarcinoma, or biliary tract carcinoma
- Measurable disease according to RECIST v1.1 and at least 1 additional site of disease amenable to biopsy
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Aged ≥18 years at time of signing informed consent
- Adequate organ function
Key Exclusion Criteria:
- Previous solid organ or hematopoietic cell transplant
- Evidence of rapid disease progression, defined as radiographic or clinical progression within 3 months of the most recent prior line of therapy
- Known history of hepatitis B or HIV infection
- Previous or concurrent malignancy except if curatively treated more than 3 years prior to enrollment
- Known active central nervous system (CNS) metastases
- Clinically significant pleural or pericardial effusion or peritoneal carcinomatosis
- Active treatment with antiviral agents
- History of severe hypersensitivity to fludarabine or cyclophosphamide
- Prior therapies/treatments with oncolytic viruses or T cell derived cellular therapy
Additional criteria apply and should be discussed with the study site.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:DISP-10
Participants will receive DV-10 in combination with ide-cel. Lymphodepleting chemotherapy (fludarabine and cyclophosphamide) will be administered a few days prior to ide-cel. |
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce ide-cel. During ide-cel production, participants may receive bridging therapy for disease control per Investigator discretion. DV-10 administration will be followed by lymphodepleting chemotherapy (fludarabine and cyclophosphamide) and subsequent ide-cel administration. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Treatment Emergent Adverse Events (TEAEs)
時間枠:90 days (2 years for related Serious Adverse Events)
|
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0 |
90 days (2 years for related Serious Adverse Events)
|
|
Incidence of Dose Limiting Toxicities (DLTs) [PART 1]
時間枠:28 days
|
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0 |
28 days
|
|
Identification of the Recommended Dose for Expansion (RDE) [PART 1]
時間枠:Up to 2 years
|
To select the Recommended Dose for Expansion (RDE) for Part 2 |
Up to 2 years
|
|
Overall response rate (ORR) [PART 2]
時間枠:Up to 2 years
|
Confirmed complete response (CR) or partial response (PR), per RECIST v1.1 |
Up to 2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall response rate (ORR) [PART 1]
時間枠:Up to 2 years
|
Confirmed CR or PR, per RECIST v1.1 |
Up to 2 years
|
|
Disease control rate (DCR)
時間枠:Up to 2 years
|
Proportion of participants with CR, PR, or stable disease per RECIST v1.1 |
Up to 2 years
|
|
Duration of response (DOR)
時間枠:Up to 2 years
|
Time from CR or PR to radiographic progression or death |
Up to 2 years
|
|
Progression Free Survival (PFS)
時間枠:Up to 2 years
|
Time from ide-cel administration to disease progression or death, whichever occurs first |
Up to 2 years
|
|
Overall survival (OS)
時間枠:Up to 15 years
|
Time from ide-cel administration to death |
Up to 15 years
|
|
Time to response (TTR)
時間枠:Up to 2 years
|
Time from ide-cel administration to the first documentation of objective tumor response |
Up to 2 years
|
|
Cellular kinetics (CK) of ide-cel
時間枠:Up to 2 years
|
Measurement of ide-cel CK in the blood |
Up to 2 years
|
|
Pharmacokinetics of DV-10 - Cmax
時間枠:Up to 2 years
|
Maximum concentration in blood |
Up to 2 years
|
|
Pharmacokinetics of DV-10 - Tmax
時間枠:Up to 2 years
|
Time to maximum concentration in blood |
Up to 2 years
|
|
Pharmacokinetics of DV-10 - AUC
時間枠:Up to 2 years
|
Area under the blood concentration curve |
Up to 2 years
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。